Shares of Myriad Genetics fell 46.1% after the genetic testing company reported second-quarter 2026 results that missed Wall Street expectations and slashed its full-year revenue guidance. Revenue came in at $190.7 million, down 10.5% year-over-year and below analyst projections, while the adjusted loss per share of $0.25 was significantly wider than anticipated. The company cut its full-year revenue forecast to a midpoint of $780 million, a decrease of over 10% from its previous outlook, signaling continued business challenges. The stock is down 53.3% year-to-date and trading at $2.87 per share, 65% below its 52-week high of $8.18 from November 2025.
Myriad Genetics IncMissed Q2 expectations and slashed full-year revenue guidance, causing a 46% plunge.